Clinical Trials & Research
Search Clinical Trials
|Title||Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma|
|Description||The purpose of this phase III trial is to study rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma.|
Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.
It is not yet known which combination chemotherapy regimen is more effective when given with rituximab in treating diffuse large B-cell non-Hodgkin's lymphoma.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years or older
* Patient must have histologically confirmed* de novo B-cell non-Hodgkin's lymphoma (NHL) of 1 of the following WHO histologic subtypes:
* Diffuse large cell lymphoma, including any of the following morphologic variants:
* Mediastinal (thymic) large cell lymphoma
* Intravascular large cell lymphoma
* NOTE: Fine needle aspirates or core biopsies must not be the only diagnostic material.
* Patient must have Stage I primary mediastinal (thymic) OR stage II-IV disease
* Patient must have CD20-positive disease
|Principal Investigator||Samir Parekh, MD|
|Contact Name||Dale Wyville, PA|
|Current Trial Type||Interventional|
|Montefiore Clinical Trial||No|
|CHAM Clinical Trial||No|